Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With
174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Milestone Scientific Inc. (MLSS) is a biomedical technology research
and development company that patents, designs, develops and
commercializes innovative diagnostic and therapeutic injection
technologies and instruments for medical, dental, cosmetic and
veterinary applications. Milestone's computer-controlled systems are
designed to make injections precise, efficient, and virtually painless.
Milestone’s proprietary DPS® Dynamic Pressure Sensing
technology® platform advances the development of next-generation
devices, regulating flow rate and monitoring pressure from the tip of
the needle, through platform extensions for local anesthesia for
subcutaneous drug delivery, with specific applications for cosmetic
botulinum toxin injections, epidural space identification in regional
anesthesia procedures, and intra-articular joint injections.
The presentation summarizes IntelGenx, a drug delivery company focused on oral thin film technologies. It discusses IntelGenx's product pipeline including treatments for migraines, erectile dysfunction, schizophrenia, and brain degenerative diseases. The presentation also outlines IntelGenx's strategic partnerships, new manufacturing facility, strengthened management team, and recent financial performance.
Presentation from OIS@ASCRS 2016
Amar Sawhney, PhD, President, CEO & Chairman
Video Presentation:
https://www.youtube.com/watch?v=nGQzo6czij0&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=31
The presentation summarizes IntelGenx, a drug delivery company focused on oral thin film technologies. It discusses IntelGenx's strategy to develop and commercialize improved drug delivery products using its oral thin film platform. Key points include successful commercial partnerships, a robust product pipeline including generic and branded products, positive clinical trial results, and a new manufacturing facility positioned for growth. Financial results show increasing revenue and adjusted EBITDA. The presentation positions IntelGenx as a leader in oral thin films with innovative technology and a clear strategy for growth.
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With
174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Milestone Scientific Inc. (MLSS) is a biomedical technology research
and development company that patents, designs, develops and
commercializes innovative diagnostic and therapeutic injection
technologies and instruments for medical, dental, cosmetic and
veterinary applications. Milestone's computer-controlled systems are
designed to make injections precise, efficient, and virtually painless.
Milestone’s proprietary DPS® Dynamic Pressure Sensing
technology® platform advances the development of next-generation
devices, regulating flow rate and monitoring pressure from the tip of
the needle, through platform extensions for local anesthesia for
subcutaneous drug delivery, with specific applications for cosmetic
botulinum toxin injections, epidural space identification in regional
anesthesia procedures, and intra-articular joint injections.
The presentation summarizes IntelGenx, a drug delivery company focused on oral thin film technologies. It discusses IntelGenx's product pipeline including treatments for migraines, erectile dysfunction, schizophrenia, and brain degenerative diseases. The presentation also outlines IntelGenx's strategic partnerships, new manufacturing facility, strengthened management team, and recent financial performance.
Presentation from OIS@ASCRS 2016
Amar Sawhney, PhD, President, CEO & Chairman
Video Presentation:
https://www.youtube.com/watch?v=nGQzo6czij0&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=31
The presentation summarizes IntelGenx, a drug delivery company focused on oral thin film technologies. It discusses IntelGenx's strategy to develop and commercialize improved drug delivery products using its oral thin film platform. Key points include successful commercial partnerships, a robust product pipeline including generic and branded products, positive clinical trial results, and a new manufacturing facility positioned for growth. Financial results show increasing revenue and adjusted EBITDA. The presentation positions IntelGenx as a leader in oral thin films with innovative technology and a clear strategy for growth.
Posterior Segment Company Showcase - Ocular TherapeutixHealthegy
Posterior Segment Company Showcase - Ocular Therapeutix at OIS@AAO 2016.
Presenter:
Amar Sawhney, PhD, President, CEO & Chairman
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
IntelGenX Investor Presentation March 30 2017 ItelGenx
The presentation provides an overview of IntelGenx Corp, an innovative drug delivery company. It discusses IntelGenx's product pipeline including oral thin film versions of migraine, erectile dysfunction, and schizophrenia drugs. It also highlights a repurposed montelukast film for mild cognitive impairment currently in clinical trials. The presentation outlines IntelGenx's business strategy, partnership with Chemo, new manufacturing facility, and management team. It concludes that IntelGenx has a solid platform for growth due to its significant market potential and ability to build strategic partnerships.
OPT-302 is a soluble form of VEGFR-3 that inhibits VEGF-C and VEGF-D, blocking their binding to VEGFR-2 and VEGFR-3. It is being developed in combination with anti-VEGF-A therapies for the treatment of wet AMD. A Phase 1/2A clinical trial is actively recruiting wet AMD patients to evaluate the safety, pharmacokinetics, and efficacy of multiple doses of intravitreal OPT-302 in combination with ranibizumab. Preliminary data is expected in early 2016, with the goal of demonstrating OPT-302 can improve outcomes when added to anti-VEGF-A therapy by more completely suppressing the VEGF pathway.
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
1) ForSight Vision5 is developing the Helios Ocular Insert, a biodegradable insert placed in the eye by a physician that is designed to slowly release bimatoprost over 6 months to lower intraocular pressure and improve patient adherence to glaucoma treatment.
2) Phase 1 and 2 clinical trials showed the insert was well-tolerated and provided sustained IOP-lowering for up to 6 months from a single administration.
3) The company plans to begin a Phase 3 clinical trial program in early 2016 to support regulatory approval and commercialization of the Helios Insert for glaucoma.
This investor presentation provides an overview of IntelGenx Corp., an innovative drug delivery solutions company. It discusses IntelGenx's pipeline of oral thin film products, including products for migraines, erectile dysfunction, schizophrenia/bipolar disorder, and mild cognitive impairment. The presentation highlights IntelGenx's strategic partnerships, new manufacturing facility, strengthened management team, and recent financial performance. It concludes that IntelGenx has established a solid platform for growth by leveraging its oral thin film technology and implementing a product sourcing strategy to identify high-value opportunities.
IntelGenx is a drug delivery company that develops improved versions of approved drugs using its proprietary drug delivery platforms, VersaFilm and AdVersa. Some of its pipeline products include Rizaport for migraines, Tadalafil VersaFilm for erectile dysfunction, Loxapine VersaFilm for schizophrenia, and Montelukast VersaFilm for mild cognitive impairment. The company has completed clinical trials demonstrating its products offer benefits over existing drugs such as increased bioavailability and reduced side effects. IntelGenx licenses its products to partners and retains manufacturing rights to generate revenue through milestone payments and royalties.
This investor presentation provides an overview of IntelGenx Corp., an innovative drug delivery solutions company. It discusses IntelGenx's product pipeline including oral thin film versions of migraine, erectile dysfunction, and schizophrenia/bipolar drugs. The presentation highlights IntelGenx's strategic partnerships, new manufacturing facility, strengthened management team, and financial performance over recent years. It positions IntelGenx for continued growth by leveraging its drug delivery platform and oral thin film technology.
SWiNTsplint is developing an implant to improve bone healing in spinal fractures. It will target orthopedic surgeons, hospitals, and patients with spinal fractures. Surgeons are the primary drivers of new product adoption but hospital administrators must approve purchases. SWiNTsplint plans to market directly to hospitals and negotiate individual pricing agreements given the small volumes expected initially. Educating surgeons at conferences and building relationships with scientific advisors and key opinion leaders will be important for gaining interest in the new product.
The document discusses the launch and goals of the Cell Therapy Catapult. The Catapult was launched to address barriers to commercializing cell therapies in the UK and grow a substantial cell therapy industry. Its goals are to increase the number of cell therapies in clinical trials, create investable companies and propositions, and demonstrate that the UK is a leader in cell therapy development. It will provide various services to support companies and aims to build a £10 billion cell therapy industry in the UK.
The document discusses InnFocus, a surgical alternative for glaucoma. It is currently in its final FDA phase of trials and has CE Mark approval in Europe. Clinical trials show it is a safe and effective procedure that lowers intraocular pressure to below 14 mmHg in over 80% of patients. It provides over a 50% reduction in pressure from baseline and allows over 70% of patients to discontinue glaucoma medications after 3 years. The outcomes meet the standards for preventing vision loss progression according to the AGIS study. InnFocus represents a promising new treatment option for the large and growing glaucoma market.
Anterior Segment Company Showcase - Mynosys Cellular DevicesHealthegy
This document discusses the ZeptoTM Capsulotomy System, a new device for performing capsulotomies during cataract surgery. The system uses femtosecond laser technology to perform automated, precise capsulotomies. Clinical experience with the device in 34 patients showed it created tag-free, complete capsulotomies with no complications. Upcoming clinical studies in the US and EU are planned to obtain regulatory approval, with market introduction expected in select countries starting in January 2017. The ZeptoTM system is presented as satisfying unmet needs by maintaining surgical efficiency while allowing capsulotomies for difficult cases like small pupils or weak zonules.
Icon Bioscience is developing improved ophthalmic drugs using its proprietary Verisome® technology to enable controlled, extended drug release with a single injection. Its lead product, IBI-10090, is a Verisome® formulation of dexamethasone for post-cataract surgery inflammation that has completed successful Phase 2 and 3 trials. Icon has a pipeline of additional ophthalmic products in development and expects to file an NDA for IBI-10090 in late 2015/early 2016, with potential to generate over $500 million in annual sales in the US alone. Icon aims to address large, unsatisfied ophthalmic markets through more convenient drug delivery with its Verisome® platform.
Bilcare GCS Packaging and Labeling CapabilitiesBilcare GCS
Bilcare GCS offers formulation development, clinical manufacturing, packaging, and labeling services to pharmaceutical and consumer healthcare clients. They have experienced scientists and state-of-the-art facilities to efficiently develop innovative formulations. Bilcare aims to help clients overcome challenges and accelerate time to market. Their integrated services allow seamless product development from formulation through clinical trials and commercialization. Bilcare has extensive experience producing various dosage forms and packaging configurations for clinical trials.
Presentation from OIS@ASCRS 2016
Dave Van Meter, President & CEO
Video Presentations:
https://www.youtube.com/watch?v=aisY-FTnTyM&index=26&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw
IntelGenx March 13, 2017 Investor PresentationItelGenx
This presentation provides an overview of IntelGenx Corp., a drug delivery company focused on oral thin film technologies. Key points include:
- IntelGenx has a pipeline of product candidates using its VersaFilm drug delivery technology, including products for migraines, erectile dysfunction, schizophrenia, and repurposing drugs for brain diseases.
- The company has completed construction of a new manufacturing facility to produce oral thin films and lower costs.
- Management believes IntelGenx is well positioned for growth due to its drug delivery expertise, business model focusing on drug repurposing and first-to-file generics, and competitive manufacturing capabilities.
IntelGenx is an innovative pharmaceutical film company presenting its product pipeline and technology platforms to investors. The presentation discusses IntelGenx's oral thin film and buccal film technologies, product development strategies, business model, pipeline of products including treatments for migraines, erectile dysfunction, and brain degenerative diseases, and clinical trial results. It highlights a de-risked product candidate using montelukast to treat brain degenerative diseases and significant market opportunities for its pipeline products.
This document discusses a clinical trial being conducted by Ocata Therapeutics to evaluate the safety and efficacy of retinal pigment epithelium (RPE) cell transplantation for dry age-related macular degeneration (AMD). Previous phase 1 trials showed anatomical engraftment and functional improvement in vision. The current phase 2 trial will evaluate three regimens of short-term immunosuppression to prevent rejection of the transplanted cells. Safety will be the primary outcome measured with the goal of establishing a protocol to maintain graft survival without long-term immunosuppression.
This presentation provides an overview of IntelGenx, a drug delivery company focused on oral thin film technologies. It discusses IntelGenx's VersaFilm and VersaTab platforms for improving drug delivery and their applications in large markets like migraines, erectile dysfunction, and schizophrenia. Key highlights include European approval of their migraine treatment Rizaport, positive bioequivalence studies for an erectile dysfunction film, and their new manufacturing facility positioning the company for growth. Financial results for 2015 show record revenue and net income, demonstrating strong execution of the company's strategy.
Anteo Technologies - New York presentation 2015Matt Sanderson
- Anteo Diagnostics is an Australian biotechnology company that develops proprietary surface coatings called Mix&Go for use in healthcare, life sciences, and other industries.
- Mix&Go is a universal double-sided molecular coating that gently but strongly binds biomolecules to synthetic surfaces, addressing challenges in test miniaturization and cost reduction.
- Anteo's growth strategy includes licensing its intellectual property, expanding its coating technologies and applications, developing product pipelines that demonstrate Mix&Go's uses, exploring new market opportunities, and acquiring synergistic assets.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical and dental applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, virtually painless, and less expensive. Milestone’s proprietary DPS® Dynamic Pressure Sensing technology® platform advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for epidural space identification in regional anesthesia procedures.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical and dental applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, virtually painless, and less expensive. Milestone’s proprietary DPS® Dynamic Pressure Sensing technology® platform advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for epidural space identification in regional anesthesia procedures.
Posterior Segment Company Showcase - Ocular TherapeutixHealthegy
Posterior Segment Company Showcase - Ocular Therapeutix at OIS@AAO 2016.
Presenter:
Amar Sawhney, PhD, President, CEO & Chairman
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
IntelGenX Investor Presentation March 30 2017 ItelGenx
The presentation provides an overview of IntelGenx Corp, an innovative drug delivery company. It discusses IntelGenx's product pipeline including oral thin film versions of migraine, erectile dysfunction, and schizophrenia drugs. It also highlights a repurposed montelukast film for mild cognitive impairment currently in clinical trials. The presentation outlines IntelGenx's business strategy, partnership with Chemo, new manufacturing facility, and management team. It concludes that IntelGenx has a solid platform for growth due to its significant market potential and ability to build strategic partnerships.
OPT-302 is a soluble form of VEGFR-3 that inhibits VEGF-C and VEGF-D, blocking their binding to VEGFR-2 and VEGFR-3. It is being developed in combination with anti-VEGF-A therapies for the treatment of wet AMD. A Phase 1/2A clinical trial is actively recruiting wet AMD patients to evaluate the safety, pharmacokinetics, and efficacy of multiple doses of intravitreal OPT-302 in combination with ranibizumab. Preliminary data is expected in early 2016, with the goal of demonstrating OPT-302 can improve outcomes when added to anti-VEGF-A therapy by more completely suppressing the VEGF pathway.
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
1) ForSight Vision5 is developing the Helios Ocular Insert, a biodegradable insert placed in the eye by a physician that is designed to slowly release bimatoprost over 6 months to lower intraocular pressure and improve patient adherence to glaucoma treatment.
2) Phase 1 and 2 clinical trials showed the insert was well-tolerated and provided sustained IOP-lowering for up to 6 months from a single administration.
3) The company plans to begin a Phase 3 clinical trial program in early 2016 to support regulatory approval and commercialization of the Helios Insert for glaucoma.
This investor presentation provides an overview of IntelGenx Corp., an innovative drug delivery solutions company. It discusses IntelGenx's pipeline of oral thin film products, including products for migraines, erectile dysfunction, schizophrenia/bipolar disorder, and mild cognitive impairment. The presentation highlights IntelGenx's strategic partnerships, new manufacturing facility, strengthened management team, and recent financial performance. It concludes that IntelGenx has established a solid platform for growth by leveraging its oral thin film technology and implementing a product sourcing strategy to identify high-value opportunities.
IntelGenx is a drug delivery company that develops improved versions of approved drugs using its proprietary drug delivery platforms, VersaFilm and AdVersa. Some of its pipeline products include Rizaport for migraines, Tadalafil VersaFilm for erectile dysfunction, Loxapine VersaFilm for schizophrenia, and Montelukast VersaFilm for mild cognitive impairment. The company has completed clinical trials demonstrating its products offer benefits over existing drugs such as increased bioavailability and reduced side effects. IntelGenx licenses its products to partners and retains manufacturing rights to generate revenue through milestone payments and royalties.
This investor presentation provides an overview of IntelGenx Corp., an innovative drug delivery solutions company. It discusses IntelGenx's product pipeline including oral thin film versions of migraine, erectile dysfunction, and schizophrenia/bipolar drugs. The presentation highlights IntelGenx's strategic partnerships, new manufacturing facility, strengthened management team, and financial performance over recent years. It positions IntelGenx for continued growth by leveraging its drug delivery platform and oral thin film technology.
SWiNTsplint is developing an implant to improve bone healing in spinal fractures. It will target orthopedic surgeons, hospitals, and patients with spinal fractures. Surgeons are the primary drivers of new product adoption but hospital administrators must approve purchases. SWiNTsplint plans to market directly to hospitals and negotiate individual pricing agreements given the small volumes expected initially. Educating surgeons at conferences and building relationships with scientific advisors and key opinion leaders will be important for gaining interest in the new product.
The document discusses the launch and goals of the Cell Therapy Catapult. The Catapult was launched to address barriers to commercializing cell therapies in the UK and grow a substantial cell therapy industry. Its goals are to increase the number of cell therapies in clinical trials, create investable companies and propositions, and demonstrate that the UK is a leader in cell therapy development. It will provide various services to support companies and aims to build a £10 billion cell therapy industry in the UK.
The document discusses InnFocus, a surgical alternative for glaucoma. It is currently in its final FDA phase of trials and has CE Mark approval in Europe. Clinical trials show it is a safe and effective procedure that lowers intraocular pressure to below 14 mmHg in over 80% of patients. It provides over a 50% reduction in pressure from baseline and allows over 70% of patients to discontinue glaucoma medications after 3 years. The outcomes meet the standards for preventing vision loss progression according to the AGIS study. InnFocus represents a promising new treatment option for the large and growing glaucoma market.
Anterior Segment Company Showcase - Mynosys Cellular DevicesHealthegy
This document discusses the ZeptoTM Capsulotomy System, a new device for performing capsulotomies during cataract surgery. The system uses femtosecond laser technology to perform automated, precise capsulotomies. Clinical experience with the device in 34 patients showed it created tag-free, complete capsulotomies with no complications. Upcoming clinical studies in the US and EU are planned to obtain regulatory approval, with market introduction expected in select countries starting in January 2017. The ZeptoTM system is presented as satisfying unmet needs by maintaining surgical efficiency while allowing capsulotomies for difficult cases like small pupils or weak zonules.
Icon Bioscience is developing improved ophthalmic drugs using its proprietary Verisome® technology to enable controlled, extended drug release with a single injection. Its lead product, IBI-10090, is a Verisome® formulation of dexamethasone for post-cataract surgery inflammation that has completed successful Phase 2 and 3 trials. Icon has a pipeline of additional ophthalmic products in development and expects to file an NDA for IBI-10090 in late 2015/early 2016, with potential to generate over $500 million in annual sales in the US alone. Icon aims to address large, unsatisfied ophthalmic markets through more convenient drug delivery with its Verisome® platform.
Bilcare GCS Packaging and Labeling CapabilitiesBilcare GCS
Bilcare GCS offers formulation development, clinical manufacturing, packaging, and labeling services to pharmaceutical and consumer healthcare clients. They have experienced scientists and state-of-the-art facilities to efficiently develop innovative formulations. Bilcare aims to help clients overcome challenges and accelerate time to market. Their integrated services allow seamless product development from formulation through clinical trials and commercialization. Bilcare has extensive experience producing various dosage forms and packaging configurations for clinical trials.
Presentation from OIS@ASCRS 2016
Dave Van Meter, President & CEO
Video Presentations:
https://www.youtube.com/watch?v=aisY-FTnTyM&index=26&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw
IntelGenx March 13, 2017 Investor PresentationItelGenx
This presentation provides an overview of IntelGenx Corp., a drug delivery company focused on oral thin film technologies. Key points include:
- IntelGenx has a pipeline of product candidates using its VersaFilm drug delivery technology, including products for migraines, erectile dysfunction, schizophrenia, and repurposing drugs for brain diseases.
- The company has completed construction of a new manufacturing facility to produce oral thin films and lower costs.
- Management believes IntelGenx is well positioned for growth due to its drug delivery expertise, business model focusing on drug repurposing and first-to-file generics, and competitive manufacturing capabilities.
IntelGenx is an innovative pharmaceutical film company presenting its product pipeline and technology platforms to investors. The presentation discusses IntelGenx's oral thin film and buccal film technologies, product development strategies, business model, pipeline of products including treatments for migraines, erectile dysfunction, and brain degenerative diseases, and clinical trial results. It highlights a de-risked product candidate using montelukast to treat brain degenerative diseases and significant market opportunities for its pipeline products.
This document discusses a clinical trial being conducted by Ocata Therapeutics to evaluate the safety and efficacy of retinal pigment epithelium (RPE) cell transplantation for dry age-related macular degeneration (AMD). Previous phase 1 trials showed anatomical engraftment and functional improvement in vision. The current phase 2 trial will evaluate three regimens of short-term immunosuppression to prevent rejection of the transplanted cells. Safety will be the primary outcome measured with the goal of establishing a protocol to maintain graft survival without long-term immunosuppression.
This presentation provides an overview of IntelGenx, a drug delivery company focused on oral thin film technologies. It discusses IntelGenx's VersaFilm and VersaTab platforms for improving drug delivery and their applications in large markets like migraines, erectile dysfunction, and schizophrenia. Key highlights include European approval of their migraine treatment Rizaport, positive bioequivalence studies for an erectile dysfunction film, and their new manufacturing facility positioning the company for growth. Financial results for 2015 show record revenue and net income, demonstrating strong execution of the company's strategy.
Anteo Technologies - New York presentation 2015Matt Sanderson
- Anteo Diagnostics is an Australian biotechnology company that develops proprietary surface coatings called Mix&Go for use in healthcare, life sciences, and other industries.
- Mix&Go is a universal double-sided molecular coating that gently but strongly binds biomolecules to synthetic surfaces, addressing challenges in test miniaturization and cost reduction.
- Anteo's growth strategy includes licensing its intellectual property, expanding its coating technologies and applications, developing product pipelines that demonstrate Mix&Go's uses, exploring new market opportunities, and acquiring synergistic assets.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical and dental applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, virtually painless, and less expensive. Milestone’s proprietary DPS® Dynamic Pressure Sensing technology® platform advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for epidural space identification in regional anesthesia procedures.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical and dental applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, virtually painless, and less expensive. Milestone’s proprietary DPS® Dynamic Pressure Sensing technology® platform advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for epidural space identification in regional anesthesia procedures.
Milestone Scientific Inc. is a leading developer of computerized drug delivery instruments that provide painless injections. They have entered the large worldwide dental market and believe their pressure force feedback and pulse wave technologies will help improve healthcare outcomes at lower costs across multiple medical areas. Recent studies showed their CompuFlo epidural instrument can save over $500 per hospital stay on average. New CompuWave and CathCheck features allow verification of epidural and catheter placement in real time, saving significant time and costs compared to traditional techniques. Milestone sees opportunities in peripheral nerve blocks, thoracic catheters, intra-articular injections and more, supported by their expanding patent portfolio.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical and dental applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, virtually painless, and less expensive. Milestone’s proprietary DPS® Dynamic Pressure Sensing technology® platform advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for epidural space identification in regional anesthesia procedures.
This presentation provides an overview of IntelGenx Corp, an innovative drug delivery company. It discusses IntelGenx's focus on using oral thin film technology to improve drug delivery and its product pipeline, which includes films for migraines, erectile dysfunction, schizophrenia, and mild cognitive impairment. The presentation also provides financial results, noting revenue growth and net income, as well as IntelGenx's new manufacturing facility and strengthened management team.
John Ludlow presented on regenerative medicine past, present, and future. He discussed early work in organ transplantation and tissue engineering. Currently, there are over 50 companies developing regenerative medicine products and the field is starting to provide commercialized solutions. However, the path has not been straightforward. Moving forward, success may come from focusing on clinical and commercial viability, strategic intellectual property management, and iterative technology evolution driven by clinical needs. The future of regenerative medicine may include more personalized and rapid regenerative options.
Ebers and biogaran innovation challengeFacundo Noya
Ebers is a startup specialized in diabetic foot care and prevention. Our principal solution are smart insole that combines pressure, temperature and humidity measure with algorithm to alert early for any risk to diabetic patients.
The document summarizes the goals and business model of the Global Regenerative Group, which aims to advance regenerative medicine through various initiatives. The Global Regenerative Academy will provide formal regenerative medicine education and facilitate clinical trials to establish evidence. It will host international conferences to connect doctors. The Global Regenerative Trade will distribute medical devices that are scientifically and clinically proven. The Global Regenerative Journal will publish peer-reviewed research. Together these initiatives seek to overcome current issues in regenerative medicine education and promote evidence-based practice, with the goal of enabling healthier aging through regenerative techniques.
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...Business Turku
This presentation provides an overview of Orion's new strategy from a midsize pharmaceutical perspective. It discusses Orion's business segments and key financial metrics. It then summarizes major pharmaceutical industry trends, including aging populations, advances in technology, and increased regulation. Finally, it outlines Orion's strategic growth target of €1.5 billion in net sales by 2025 and focus areas to achieve this, such as delivering its late-stage portfolio, building its pipeline, maximizing the value of existing assets, and exploring new partnerships and technologies.
Presentation from OIS@ASCRS 2016
Co-Moderators:
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Stephen Slade, MD
Company Presentations
Equinox | John Berdahl, MD, Founder & CEO
Presbyopia Therapies | Jim McCollum, Co-Founder
Stroma Medical | Doug Daniels, CEO
Eyenovia | Curt LaBelle, MD, Director
Wicab | Robert Beckman, President & COO
This document discusses trends in the global healthcare industry and strategies for sustainability. It notes that healthcare spending is projected to triple globally by 2020 due to factors like aging populations and rising standards of living. However, patients often do not receive recommended care for common conditions and medical errors are a leading cause of death. The document outlines seven features of sustainable healthcare systems: establishing common ground; developing a digital infrastructure; realigning financial incentives; implementing quality standards; strategically deploying resources; fostering innovation; and enabling adaptable roles. It provides examples of countries that have implemented policies aligned with these features to control costs while improving outcomes.
This document discusses the need for patient-centered clinical trials due to rising complexity, costs and failure rates of traditional trials. It notes delays in enrollment are a major issue, inflating costs and timelines. Protocols have become more complex and burdensome, reducing adherence and retention. The future requires improving recruitment methods, incorporating patient needs, and placing data generation in patients' hands through technologies like social media and ePRO tools. Patient-centered approaches may help address these challenges and better support drug development.
Medvantage International has acquired rights to a new vascular coupling device called CUVASLAR that represents an alternative to manual suturing for connecting arteries and veins. The device is expected to reduce surgical time, minimize errors from suturing, and improve patient outcomes. Medvantage plans to submit the device for FDA approval over the next year and market it to the 340,000 microsurgery procedures performed annually in the US.
The document summarizes news from the medical device industry. Specifically, it discusses:
1) The FDA clearance of Lumendi's Dilumen endoscopic accessory, which uses balloons to help position an endoscope and treat colonic lesions. This represents a minimally invasive alternative to surgery.
2) Varian Medical Systems' plan to spin off its imaging components business to boost its valuation after a difficult year.
3) Continued growth in patent filings from China, including in medical devices, cementing its status as an innovation leader according to the World Intellectual Property Organization.
4) Blackfynn's neurology data platform that aims to advance research by aggregating data, with
Vivos Inc. presented a new brachytherapy tool called RadioGel for treating cancers in humans and animals. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle. It is designed to deliver a high radiation dose directly to tumors while minimizing damage to healthy tissue. The company expects to generate near-term revenue from veterinary applications and international licensing as it pursues FDA approval for multiple human cancer indications starting with skin cancer. Vivos has strong leadership and advisors in place and an intellectual property protected platform technology to become an important new tool for cancer treatment.
Glaukos Corporation is an ophthalmic medical technology company transforming glaucoma treatment. Their minimally-invasive micro-scale injectable therapies, including the iStent, provide more effective treatment options compared to eye drops and traditional surgeries. Clinical trials demonstrate the iStent used with cataract surgery significantly lowers intraocular pressure up to 3 years post-op while reducing medication use. Additional studies show promise for combination treatments and sustained efficacy of micro-scale injectable therapies.
The document is an investor presentation by IntelGenx, an innovative drug delivery solutions company. It summarizes the company's business strategy, product pipeline, and financial performance. Key points include IntelGenx's focus on repurposing drugs using its oral thin film technology, its partnerships with companies like RedHill and Chemo, its pipeline of products including treatments for migraines and erectile dysfunction, and the construction of its new manufacturing facility. The presentation highlights IntelGenx's potential for growth in the oral thin films market.
The document discusses the UK medical device market and the NHS. It describes M3AT's attempts to develop and fast track innovative medical devices to NHS patients. Specifically, it discusses M3AT's development of Urocomfor, a new urine management system. Urocomfor provides benefits to patients by improving autonomy and dignity. It benefits nurses by freeing them from unnecessary tasks. For hospitals, it can reduce costs from infections and accidents while improving patient satisfaction. However, start-up companies like M3AT find it difficult to get innovative devices through the NHS supply chain process and contracts.
Similar to Milestone Scientific Inc. Investor Presentation November (20)
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
Docola has developed a healthcare communication platform that utilizes asynchronous telehealth to deliver patient education and support. Their proprietary platform currently has over 55,000 patient users and over 1,100 clinician users. Docola seeks to raise up to $500,000 through a convertible note to fund working capital, research and development, and costs associated with an upcoming IPO.
- INNO Holdings is presenting an IPO investor presentation for an initial public offering on the NASDAQ Capital Market.
- The company manufactures prefabricated steel building components and systems using proprietary technology to reduce construction costs and environmental impact.
- INNO Holdings has four initial product lines - metal studs, prefabricated housing units, modular apartment buildings, and a mobile factory system. It aims to disrupt the construction industry through standardized, sustainable construction methods.
Everything Blockchain builds platforms of trust for the modern enterprise and is on a mission to ensure every organization has access to the tools and platforms that enable them to manage, store, and protect data without the cost and complexity that holds them back today. The Company’s patented advances in engineering deliver the essential elements needed for real-world business use: speed, security, and efficiency. Everything Blockchain’s current business lines include: EB Advise, Build DB and EB Control.
ASP Isotope is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Digital Ally, Inc. is a diversified holding company with operations in video solution technology, human and animal health protection products, healthcare revenue cycle management, ticket brokering and marketing, and event production. The Company pursues an acquisition strategy that targets organizations with positive earnings, strong growth potential, innovation, and operational synergies. To maximize long-term shareholder value, Digital Ally intends to spin-off its ticketing and entertainment business lines into a separate public company in 2023. The spin-off will create two optimized, tech-driven public companies with strong growth opportunities and operating metrics.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
Aditxt is a biotech company developing immune monitoring and immune modulation platforms. Its AditxtScore platform can provide comprehensive immune profiles to monitor responses to pathogens, vaccines, drugs and transplants. Its Adimune platform aims to modulate the immune system to treat conditions like psoriasis, type 1 diabetes, and increase skin allograft survival. The company is working to develop, operate and commercialize these platforms. It currently generates revenue from immune monitoring tests and expects revenue from licensing deals for immune modulation programs as they advance in clinical trials towards commercialization.
1847 Holdings LLC, a publicly traded diversified acquisition holding company, was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue and Principal of Lazard Freres Strategic Realty Investors. EFSH's investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises and lower-middle market businesses with limited exit options, despite the intrinsic value of their business. Given this dynamic, EFSH can consistently acquire "solid" businesses for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at considerably higher valuations than the purchase price (as successfully demonstrated with the mid-2020 IPO of 1847 Goedeker on the NYSE American) and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to EFSH's ability to pay regular and special dividends to shareholders.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. The Company has three core divisions: SolarJuice which has solar wholesale distribution, as well as residential solar and roofing installation and solar module manufacturing (Solar4America & SEM Wafertech), SPI Solar and Orange Power which operates a commercial & utility solar division, and the EdisonFuture/Phoenix Motor EV division. SolarJuice is the leader in renewable energy system solutions for residential and small commercial markets and has extensive operations in the Asia Pacific and North America markets. The SPI Solar commercial & utility solar division provides a full spectrum of EPC services to third party project developers, and develops, owns and operates solar projects that sell electricity to the grid in multiple regions, including the U.S., U.K., and Europe. Phoenix Motor is a leader in medium-duty commercial electric vehicles, and is developing EV charger solutions, electric pickup trucks, electric forklifts, and other EV products. SPI maintains global operations in North America, Australia, Asia and Europe and is also targeting strategic investment opportunities in fast growing green energy industries such as battery storage, charging stations, and other EVs which leverage the Company's expertise and substantial solar cash flow.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
2. Safe Harbor Statement
This presentation contains forward-looking statements regarding the timing and financial
impact of Milestone's ability to implement its business plan, expected revenues, timing of
regulatory approvals and future success. These statements involve a number of risks and
uncertainties and are based on assumptions involving judgments with respect to future
economic, competitive and market conditions, future business decisions and regulatory
developments, all of which are difficult or impossible to predict accurately and many of
which are beyond Milestone's control. Some of the important factors that could cause actual
results to differ materially from those indicated by the forward-looking statements are
general economic conditions, failure to achieve expected revenue growth, changes in our
operating expenses, adverse patent rulings, FDA or legal developments, competitive
pressures, changes in customer and market requirements and standards, and the risk
factors detailed from time to time in Milestone's periodic filings with the Securities and
Exchange Commission, including without limitation, Milestone's Annual Report for the year
ended December 31, 2019. The forward-looking statements in this presentation are based
upon management's reasonable belief as of the date hereof. Milestone undertakes no
obligation to revise or update publicly any forward-looking statements for any reason.
2
3. Company History
With 133 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology
Milestone Scientific Inc. (MLSS) is a leading
medical research and development
company that designs and patents
innovative injection technology. Milestone's
computer-controlled systems make
injections precise, efficient, and virtually
painless.
3
4. Why Enter the Epidural Market?
Market Size
Epidural procedures are one of the fastest growing procedures in the US and worldwide. It is
estimated that over 11 million epidural procedures are performed each year in the US and over
30 million worldwide.
Over $5 billion is spent annually on epidural injections in the US alone. The approximate break
down of epidural procedures in the US is:
§ 2.4 million labor procedures out of almost 4 million births
§ 9 million pain intervention steroid injections
§ ~900,000 total and growing Neuroaxial Regional Blocks for hip and knee surgeries
4
5. Current Technology Being Used Today!
The technique of "single-shot" lumbar
epidural anesthesia was first developed
in 1921 by Spanish military surgeon
Fidel Pagés, and hasn’t changed
significantly since.
Glass Loss of Resistance
(LOR) 1946
“Modern” LOR
Syringes
5
6. Innovating a New Standard of Care
in Anesthesia
• Now with our patented
CompuWave™ and CathCheck™
features, anesthesiologists should
be able to save significant time
and institutions should save
significant costs
• Correlates subjective feel with
objective visual and audible
verification of pressure changes
• Offers real-time needle location
with consistent distinction of true
loss of resistance
• Builds physician confidence
resulting in fewer attempts; less
Dural punctures reducing
complications and costs
• Accelerates procedure learning
curve for residents and trainees
Welcome to the 21st
Century
6
7. Listening to Providers, Addressing
Unmet Needs
§ Placement of an epidural needle is difficult;
Requiring 60-90 placements before reaching an
adequate skill level
§ 17% of failure rates are due to false loss of
resistance (False Loss of resistance is when the
needle enters soft tissue or fatty tissue and the
provider believes it is in the epidural space when it
is not) resulting in a failure to provide pain relief.
This requires another attempt while the patient
remains in labor and pain.
§ Epidural Dural punctures are as high as 5+%. An
Epidural puncture is when the Dura is breached
and the needle enters into the spinal canal, causing
cerebral spinal fluid to leak resulting in headaches,
pain, infection, and other morbidities costing
insurance companies and hospitals additional time
and money.
§ 20% of epidural blood patches also fail and require
additional care (A blood patch is a procedure to try
and repair the Dural punctures)
7
8. 8
Management Team
Interim CEO
Leonard Osser
CFO/COO
Joseph D’Agostino
Over 76 years of collective commercial experience in medical with
Involvement in numerous medical product launches
President
CEO Wand Dental
Arjan Haverhals
Clinical Director
Dr. Mark
Hochman
KOL and Study Author
Dr. Giorgio Capogna
VP, US Sales
Eric Gilbert
9. CompuFlo Epidural Instrument
Commercial Momentum
§ The CompuWave™ patented feature is allowing precise
location identification of the epidural space
§ Nine peer-reviewed published studies validate instrument
effectiveness in identifying the epidural space
§ Additional ongoing studies
§ More than 2,000 epidural procedures performed
worldwide including key opinion leaders
§ Hospital in Italy adopts CompuFlo for all epidurals in
labor and delivery
§ Moving to a direct sales model in the USA
§ Study on Economic Benefit
9
10. New Clinical Trial Finds CompuFlo® Instrument a Safe
Alternative to Current Standards of Care
§ 160 labor and delivery (L&D) patients –
400 total
§ 99 % effective in identifying epidural
space on first attempt
§ 14 % more successful in patients with
high BMI
§ L&D epidurals resulted in 0 dural
punctures, loss of resistance 4 (old
technique being used today)
§ Procedure time reduced by 1 minute with
CompuFlo
ANESTHESIA & ANALGESIA
NOV 2019
10
11. Anesthesiology Research & Practice
Jan 2019
§ 120 patient clinical study
§ CompuFlo blocks performed successfully with
no complications
§ Consistent differentiation of true loss of
resistance
“The pressure sensing innovation
in CompuFlo offers a more
objective, reliable and simpler way
to identify the epidural space. This
confidence in recognizing a true
loss of resistance can help
improve the efficacy of anesthesia,
reduce complications, and speed
the procedure learning curve for
trainees.”
Dr. Giorgio Capogna
Director of the European School of
Obstetric Anesthesia and Maternal
Neonatal Simulation Center
11
12. International Journal of Obstetric Anesthesia
Nov 2018
§ Objective identification of ligamentum flavum
and epidural space
§ Difficult blocks rescued in a single attempt
§ Differentiation of true loss of resistance for
accurate epidural placement
“We [have] validated the CompuFlo
device as a means of adequately
identifying the ligamentum flavum
and the epidural space. “
“Our preliminary findings suggest
that it could assist the physician in
training when performing epidural
insertion.”
Study investigators from the Citta di
Roma Hospital and Careggi Hospital:
Dr. Giorgio Capogna,
Dr. Michela Camorcia
Dr. Alessandra Coccoluto
Dr. Massimo Micaglio
Dr. Matteo Velardo
12
13. Cost Savings Studies Underway
¡ Large academic institution completed a definitive economic study
aimed to prove:
¡ Significant reduction of accidental Dural punctures
¡ Associated cost reduction
¡ One anesthesiologist completed over 500 CompuFlo epidurals,
reporting no Dural punctures
¡ KOL relationship development in progress in France, Spain,
Germany, UK, Belgium, Italy and USA
13
14. Cost Savings of More Than $500 Per
Hospital Stay on Average
¡ Department of Anesthesiology,
University of Texas Medical Branch at
Galveston
¡ Objective: Cost effectiveness analysis
of CompuFlo with real-time pressure
sensing technology and traditional LOR
technique in parturients requesting
labor epidural anesthesia
¡ 4483 deliveries from 4353 parturients
were included in the study
¡ Conclusion: CompuFlo costs about
$504 less per hospital stay on average
¡ For a hospital with 6000 epidural
procedures per year, potential cost
savings could be 3 million dollars
14
15. § Establish CompuFlo as the preferred
procedure using the cost saving
analysis
§ Moving to a direct sales force with
clinical support personnel
§ On October 13th, 2020, the company
announced it has been awarded a
group purchasing agreement for the
CompuFlo® Epidural System and
CathCheck™ with Premier effective
November 1st, 2020. It provides
enhanced access to Premier’s
members and should help accelerate
our mission to become the standard of
care.
US Sales
¡ Over 200 physician demos
completed in over 16 hospitals
¡ Given the significant reduction of
time that CathCheck™ affords
anesthesiologists, we believe that
this will be our first point of entry
into the US hospital market.
15
Sales Strategy
16. International Sales
¡ Addition of MOVI Group in Italy
¡ 10 instruments purchased
¡ 28 sales agents in the field
¡ 1 dedicated product manager,
3 regional managers
¡ First sale by MOVI to Ospedale
“Pugliese Ciaccio” di
Cantanzaro, hospital in Italy
¡ Agreement with new Croatian
distributor, EMA d.o.o.
¡ 3 instruments purchased
¡ Trials in 4 hospitals
¡ Sales to Algeria, Diagal
¡ 6 instruments
¡ Lebanon distributor, Sterimed
¡ Presented CompuFlo at 3
congresses
¡ Trials in 2 University Hospitals in
progress
¡ MOU with Russian distributor, REAN
¡ 1 demo instrument sold to
investigate market size and
potential
¡ Presented at 4 congresses
16
17. Marketing
§ Refined market messaging to
providers
§ Invested in US live birth data by
hospital for sales targeting
§ Developed Cost Calculator App
for sales team
§ Launched a Commercial
Procedure Tracker & Reporting
Tool for loaner trials
§ Updated marketing and sales
brochures
§ Initiated Digital Marketing
Strategy
§ New packaging concept including
preassembled disposables
§ Developed CompuFlo Trainer
product to target simulation Labs
& Medical Training Centers
§ Launched CompuWave™ and
CathCheck™ features
17
19. Beyond Epidural:
The Medical Opportunity
Peripheral
Nerve Block
Thoracic
Catheter
Check
Intra-articular
ü Now with our patented CompuWave™ technology the
CompuFlo Epidural Instrument can now check catheters in
1-2 minutes not 20-40 minutes.
ü High-risk nature of procedure; 3 – 5 % of all epidurals,
Study currently underway.
ü Received peripheral nerve block patent
ü Large worldwide market for injections into the joints
ü Received US Patent in April 2020
Botox
19
20. Business Plan Summary/Strategy
§ With the market and individual hospital systems all having different criteria
and purchasing models, we will have 3 different sales strategies.
1. Sell the CompuFlo instrument and disposables.
2. Consign the CompuFlo instrument and upcharge the disposables.
3. Lease the CompuFlo instrument and disposables, we include the
instrument and a minimum number of disposables into a monthly
payment. More disposables can be purchased if they exceed the
minimum.
§ The strategy is to accommodate the different hospital systems purchasing
procedures. If consigned or leased it is a different process and often easier
and less time consuming and falls into a different budget. Often a less time
consuming process is available if the product is consigned or leased to a
hospital.
20
21. Milestone Scientific- Market Re-Cap
Epidural is one of the fastest growing segments in Medicine
§ 11 million performed in the US and 30 million worldwide
§ 2.4 million Labor and Delivery-US
§ 9 million nerve blocks for pain intervention-US
§ 900,000+ for pain blocks in Hips and Knees- US
§ Over a $5+ Billion Dollar Market in the US and growing
Peripheral Nerve Blocks (PNB)
§ Globally there are 41 million Peripheral Nerve blocks performed, US market is
expected to reach $430 Million by 2027.
§ Study performed by Dr. Oliver Choquet at the Lapeyronie University Hospital-
Montpellier concludes that high injection pressure during PNB procedures should be
avoided and pressure monitoring should be sensitive and easy to use to improve the
safety of PNB
§ With the passing of the Substance Abuse Disorder Prevention That Promotes Opioid
Recovery and Treatment for Patients and Communities (SUPPORT) act, physicians are
using more pain blocks to reduce the opioid use post surgery.
Insurance companies now require at least 3 pain injections for prognostic and diagnostic
workup prior to approving surgery in orthopedics and spine.
21
22. Two New Features added to the
CompuFlo Epidural Instrument
With the addition of the patented CompuWave™ technology we can
now not only verify epidural placement but also confirm catheter
placement in real time with the patients’ pulse
22
23. What Do These New Features Mean?
When performing an epidural
the CompuFlo™ instrument
objectively identifies the False
Loss of Resistance and True
Loss of Resistance.
CompuWave™ allows the
practitioner to also verify that
the needle is in the epidural
space when the pulsatile
waveform is displayed
False Loss of
Resistance
True Loss of
Resistance
23
24. What Do These New Features Mean?
Until now clinicians check
catheters by administering a bolus
of anesthetic to a patient and are
then required to wait 20-40
minutes to see if patient’s pain has
subsided, if it doesn’t the catheter
has to be removed and another
epidural must be performed.
With CathCheck™ they can, in 1-
2 minutes identify if the catheter
is in place or has become
dislodged from the epidural
space.
This saves considerable time and
money and provides better
patient care.
If the Catheter is in the epidural
space the waveform indicates it.
If it’s not that will be indicated
as well.
24
25. The Importance of CathCheck™
The CathCheck™ feature is unique to Milestone Scientific…the ability
to check catheters is reduced to 1-2 minutes from 20 - 40 minutes.
CathCheck™ will allow much faster verification time of the catheter
placement. Patients are often moved multiple times daily which can
lead to the catheter being dislodged from the epidural space. The
dislodgement of the catheter prevents the patients from receiving pain
relief. CathCheck™ is significantly reducing catheter placement
verification time.
CathCheck™’s ability for fast verification will considerably reduce
anesthesiologists’ time which will translate into considerable savings
to the institution and better patient care.
25